Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Year of the authorized generic

Executive Summary

Deficit Reduction Act (S 1932), which was signed into law Feb. 8, delays inclusion of "authorized generics" in "best price" calculations until Jan. 1, 2007. Both the House and Senate budget reconciliation bills originally set Jan. 1, 2006 as the date for the provision to take effect. The new "best price" formula could effectively end the practice of "authorized generics" (1"The Pink Sheet" Jan. 2, 2006, p. 25). Generic Pharmaceutical Association lauds the new formula, claiming that it would yield more than $150 mil. in savings over five years...

You may also be interested in...



Medicaid Reform Bill Is A Draw For Pharma; Pharmacy Continues Its Fight

The conference report on budget reconciliation creates a new definition of the Medicaid federal upper limit for pharmacy reimbursement for multiple source drugs

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel